Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival

Treatment of patients with Mayo stage IIIb light chain (AL) amyloidosis is still challenging, and the prognosis remains very poor. Mayo stage IIIb patients were excluded from the pivotal trial leading to the approval of daratumumab in combination with bortezomib-cyclophosphamide-dexamethasone. This...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Sara Oubari, Ute Hegenbart, Renate Schoder, Maximilian Steinhardt, Maria Papathanasiou, Tienush Rassaf, Andreas Thimm, Tim Hagenacker, Eyad Naser, Ulrich Duhrsen, Hans C. Reinhardt, Martin Kortum, Hermine Agis, Stefan Schonland, Alexander Carpinteiro
Format:	Artigo
Jezik:	Inglês
Izdano:	Ferrata Storti Foundation 2023-07-01
Serija:	Haematologica
Online dostop:	https://haematologica.org/article/view/11160
Oznake:	Označite Brez oznak, prvi označite!